StemCell Therapy

RESEARCH TRIANGLE PARK, N.C., Nov. 23, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that Jack Bailey, G1’s Chief Executive Officer, and other members of the executive team will participate virtually in the Evercore ISI HealthCONx Conference. The fireside chat with G1 will be held at 1:25PM EST on November 30, 2022. The webcast and replay of this event will be accessible on the Events & Presentations page of http://www.g1therapeutics.com.

Link:
G1 Therapeutics to Participate in the Virtual Evercore ISI HealthCONx Conference

Secures Revocation of Patent for Peptide Inhibitor of Plasma Kallikrein (PKal)

See the article here:
Oxurion Further Improves THR-149 Patent Position

NEW YORK, Nov. 23, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company enabling breakthrough CNS immunomodulation approaches to enhance the functionality of Treg-based therapies, announces publication of a scientific article in the peer-reviewed journal Frontiers in Immunology entitled “Nasal administration of anti-CD3 monoclonal antibody modulates effector CD8+ T cell function and induces a regulatory response in T cells in human subjects”(1) . The study was completed by researchers at the Brigham and Womens Hospital (BWH) and Harvard Medical School. The goal of the study was to assess safety and the immune effects of an entirely human, previously uncharacterized nasal anti-CD3 mAb (foralumab) in humans and its in vitro stimulatory properties. The findings support Tiziana’s intranasal foralumab platform as a new modality for the treatment of autoimmune and CNS diseases.

Here is the original post:
Tiziana Announces Publication of a Peer-Reviewed Article on the Intranasal Administration of Foralumab Demonstrating Modulated Effector CD8+ T cell...

NOVEMBER 23, 2022 – ANNOUNCEMENT NO. 11

Read the rest here:
Resolutions passed at the Annual General Meeting of Chr. Hansen Holding A/S

-- Dr. Smith is a 20-year pharmaceutical industry veteran with extensive central nervous system (“CNS”) clinical development expertise --VANCOUVER, British Columbia, Nov. 23, 2022 (GLOBE NEWSWIRE) -- Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (Nasdaq: DRUG) (CSE: DRUG), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders, epilepsy, and pain, today announced that Mark A. Smith M.D., Ph.D. will join the Company as Chief Medical Officer, effective December 1, 2022. The Company also announces that Dr. Revati Shreeniwas’ engagement with Bright Minds as Chief Medical Officer has been terminated.

Read the original:
Bright Minds Biosciences Appoints Drug Development Executive Mark A. Smith M.D., Ph.D. as Chief Medical Officer

Additional production runs and increased processing for the benefit of patients Additional production runs and increased processing for the benefit of patients

Read more:
Curium’s Customers to Benefit From Mo-99 Production Restart

KRAKOW, Poland, Nov. 23, 2022 (GLOBE NEWSWIRE) -- Ryvu Therapeutics (WSE:RVU), a clinical-stage drug discovery and development company focusing on novel small molecule therapies that address emerging targets in oncology, today announced third quarter 2022 financial results and provided a corporate update.

Original post:
Ryvu Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Company Announcement

Read the rest here:
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

HAMILTON, Bermuda, Nov. 23, 2022 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that management will participate in a fireside chat at the Evercore ISI 5th Annual HealthCONx Conference on Wednesday, November 30, 2022 at 10:05 a.m. Eastern Time.

Continued here:
Kiniksa Pharmaceuticals to Present at Evercore ISI 5th Annual HealthCONx Conference

AUSTIN, Texas, Nov. 23, 2022 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (ETBs), today announced that CEO, Eric Poma, Ph.D., will present a virtual fireside chat at Evercore ISI’s 5th Annual HealthCONx conference which will take place November 29 – December 1, 2022, and an in-person fireside chat with an analyst Q&A portion at Piper Sandler’s 34th Annual Healthcare Conference in New York, NY which will take place November 29 – December 1, 2022. Highlighting positive incremental data, the chats will comprise a review of the de-immunized next-generation ETB scaffold and programs. One-on-one meetings may be scheduled with banking representatives of Evercore ISI or Piper Sandler, respectively, or directly with Molecular Templates.

Read the rest here:
Molecular Templates, Inc. to Present Fireside Chats at Two Upcoming Investor Conferences: Evercore ISI’s 5th Annual HealthCONx Conference and Piper...

NEW YORK, Nov. 23, 2022 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (Nasdaq: EYEN), a pre-commercial ophthalmic technology company developing the Optejet® delivery system for use both in combination with its own drug-device therapeutic programs for mydriasis, presbyopia and pediatric progressive myopia as well as out-licensing for additional indications, today announced management will present at the BTIG Ophthalmology Day taking place virtually on November 29, 2022. Presentation details are below:

Read more here:
Eyenovia to Present at Upcoming BTIG Ophthalmology Day

NEW YORK, Nov. 23, 2022 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (Nasdaq: BYSI), a clinical stage global biopharmaceutical company focused on developing innovative cancer therapies, today announced that on November 18, 2022, it received a written notification from The Nasdaq Stock Market LLC (“Nasdaq”) that the Company is not in compliance with the requirement to maintain a minimum closing bid price of $1.00 per share, as set forth in Nasdaq Listing Rule 5550(a)(2), because the closing bid price of the Company’s ordinary shares (the “Ordinary Shares”) was below $1.00 per share for 30 consecutive business days. The notification letter does not result in the immediate delisting of the Company’s Ordinary Shares and has no current immediate effect on the listing or trading of the Company’s Ordinary Shares on Nasdaq.

Continued here:
BeyondSpring Receives Nasdaq Notice Regarding Minimum Bid Price Requirements

LONDON and BOSTON, Nov. 24, 2022 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease to address the significant unmet need in the multi-billion-dollar market, announces that the board of directors of the Company (the "Board" or "Directors"), acting on a recommendation of the Remuneration Committee has awarded Mr Raj Patil, the Company’s Chief Scientific Officer, a total of 5,000,000 options at an exercise price of 6.25 pence per share, in recognition of his work in achieving the recent IND filing for OK-101. The options vest immediately and have a life of five years.

Read the original post:
OKYO Pharma Limited – PDMR dealing

-- 2nd MAA submission in Europe reflects toripalimab’s steady yet speedy progress towards global commercialization -- 2nd MAA submission in Europe reflects toripalimab’s steady yet speedy progress towards global commercialization

Original post:
Junshi Biosciences Announces Submission of a Marketing Authorization Application for Toripalimab to the UK Medicines and Healthcare Products...

TORONTO, Nov. 24, 2022 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, announced today that it will submit the Type C meeting request package to the U.S. Food & Drug Administration (“FDA”) by mid-December 2022, which will outline the overall development plan and Pre-Dose selection data supporting the latest revised endpoints for the Company’s Phase 3 clinical trial (the “Study”) (NCT04504734) to evaluate the safety and efficacy of Bucillamine, an oral drug with anti-inflammatory and antiviral properties, in patients with mild to moderate COVID-19. Following the submission of the Type C meeting request package, the Company expects to hear from the FDA on a firm date for the meeting.

See the original post:
Revive Therapeutics Announces Update for Type C Meeting to Discuss Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the...

Company Files First 510(k) Application in Wound Care Company Files First 510(k) Application in Wound Care

Link:
Kane Biotech Announces Third Quarter 2022 Financial Results

COPENHAGEN, Denmark, November 24, 2022 – Bavarian Nordic A/S (OMX: BAVA) has today received information about the following transactions of the company’s shares/related securities by persons holding managerial responsibilities and/or persons/companies closely associated with such.

See original here:
Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies...

- Data demonstrating that Ixo-vec was generally well tolerated and that a single intravitreal (IVT) injection can lead to stable and persistent aflibercept protein levels through three years in participants in the OPTIC extension study

See the original post:
Adverum Biotechnologies Presents Positive End of Study Results from the OPTIC Trial in Wet AMD Including Two-Year Outcomes Following a Single...

04.11.2022 at 18:30

Original post:
Orion Corporation: Acquisition of Own Shares 04.11.2022

ORION CORPORATION        STOCK EXCHANGE RELEASE 4 NOVEMBER 2022 at 18.35 EET

Read this article:
Orion Corporation completed share acquisitions